 COPENHAGEN, Denmark, March 16, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper in the peer-reviewed journal Scientific Reports, describing a study into the bacterium Staphylococcus aureus S. aureus. The paper can be accessed here: 